Get started
ALNYLAM PHARMACEUTICALS INCALNYLAM PHARMACEUTICALS INCALNYLAM PHARMACEUTICALS INC

ALNYLAM PHARMACEUTICALS INC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Bonds

1ALNY chart


Full chart

1ALNY upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪33.39 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.9 EUR
Net income (FY)
‪−268.69 M‬ EUR
Revenue (FY)
‪2.17 B‬ EUR
Shares float
‪124.67 M‬
Beta (1Y)
1.19

Employees


Employees (FY)
‪2.23 K‬
Change (1Y)
+130 +6.19%
Revenue / Employee (1Y)
‪973.88 K‬ EUR
Net income / Employee (1Y)
‪−120.49 K‬ EUR

About Alnylam Pharmaceuticals, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Yvonne L. Greenstreet
Website
alnylam.com
Headquarters
Cambridge
Founded
2002
FIGI
BBG01TNW94D7
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

1ALNY news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

1ALNY highest yielding bonds


ALNY5653584
Alnylam Pharmaceuticals, Inc. 1.0% 15-SEP-2027
Yield to maturity
−6.37%
Maturity date
Sep 15, 2027

See all 1ALNY bonds 

Sparks


Curated watchlists where 1ALNY is featured.

See all sparks 


Check out other big names from the same industry as 1ALNY.

Frequently Asked Questions


The current price of 1ALNY is 255.0 EUR — it has decreased by −0.78% in the past 24 hours. Watch ALNYLAM PHARMACEUTICALS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange ALNYLAM PHARMACEUTICALS INC stocks are traded under the ticker 1ALNY.
1ALNY stock has fallen by −2.34% compared to the previous week, the month change is a 19.66% rise, over the last year ALNYLAM PHARMACEUTICALS INC has showed a 19.66% increase.
We've gathered analysts' opinions on ALNYLAM PHARMACEUTICALS INC future price: according to them, 1ALNY price has a max estimate of 447.47 EUR and a min estimate of 189.73 EUR. Watch 1ALNY chart and read a more detailed ALNYLAM PHARMACEUTICALS INC stock forecast: see what analysts think of ALNYLAM PHARMACEUTICALS INC and suggest that you do with its stocks.
1ALNY reached its all-time high on May 21, 2025 with the price of 261.1 EUR, and its all-time low was 213.1 EUR and was reached on Apr 25, 2025. View more price dynamics on 1ALNY chart.
See other stocks reaching their highest and lowest prices.
1ALNY stock is 0.78% volatile and has beta coefficient of 1.19. Track ALNYLAM PHARMACEUTICALS INC stock price on the chart and check out the list of the most volatile stocks — is ALNYLAM PHARMACEUTICALS INC there?
Today ALNYLAM PHARMACEUTICALS INC has the market capitalization of ‪32.97 B‬, it has decreased by −0.87% over the last week.
Yes, you can track ALNYLAM PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
ALNYLAM PHARMACEUTICALS INC is going to release the next earnings report on Jul 31, 2025. Keep track of upcoming events with our Earnings Calendar.
1ALNY earnings for the last quarter are −0.41 EUR per share, whereas the estimation was −0.82 EUR resulting in a 50.56% surprise. The estimated earnings for the next quarter are −0.59 EUR per share. See more details about ALNYLAM PHARMACEUTICALS INC earnings.
ALNYLAM PHARMACEUTICALS INC revenue for the last quarter amounts to ‪549.23 M‬ EUR, despite the estimated figure of ‪540.87 M‬ EUR. In the next quarter, revenue is expected to reach ‪560.21 M‬ EUR.
1ALNY net income for the last quarter is ‪−53.13 M‬ EUR, while the quarter before that showed ‪−80.91 M‬ EUR of net income which accounts for 34.34% change. Track more ALNYLAM PHARMACEUTICALS INC financial stats to get the full picture.
No, 1ALNY doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 29, 2025, the company has ‪2.23 K‬ employees. See our rating of the largest employees — is ALNYLAM PHARMACEUTICALS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ALNYLAM PHARMACEUTICALS INC EBITDA is ‪−53.44 M‬ EUR, and current EBITDA margin is −5.35%. See more stats in ALNYLAM PHARMACEUTICALS INC financial statements.
Like other stocks, 1ALNY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ALNYLAM PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.